U.S. Medtech Is Taking Over in Europe
When U.S. medtech companies acquire European firms, the deals tend to be worth much more than those of European firms taking over American concerns.
That’s according to a report by EP Vantage, which chalked the imbalance up to the fact that Europeanmedtech companies are generally smaller and less well-funded than their U.S. counterparts. Excluding Medtronic’s $50 billion purchase of Ireland’s Covidien, the biggest U.S. to Europe deals to date include:
- Johnson & Johnson’s $19 billion purchase of Synthes in 2012;
- Dentsply’s $14.5 billion merger this year withSirona;
- Baxter’s $4 billion takeover of Gambro in 2013;
- Thermo Fisher’s $3.5 billion purchase of Phadia in 2011.
In a technically in-Europe deal, Medtronic also agreed in May to buy Smith & Nephew’s gynecology unit for $350 million.
Novartis’ $51.6 billion staged takeover of Alcon, completed in 2010;The top five Europe-to-U.S. deals the service listed for 2010 to 2015 were:
- Endo International’s purchase of American Medical Systems in 2011;
- Covidien’s $2.6 billion acquisition of ev3 in 2010;
- Fresenius’ $1.7 billion of Liberty Dialysis Holdings in 2012;
- Grifols’ $1.7 billion purchase of Novartis’ blood transfusion business in 2013.
Endo later sold off the urology device business it landed through the American Medical Systems acquisition to Boston Scientific.
Read More: U.S. Medtech Is Taking Over in Europe
Nancy Crotti is a contributor to Qmed.
[Image courtesy of Pixabay]